This Quick Overview addresses how the Precision Medicine Initiative (the "PMI") allows targeted therapies to be deployed that are more likely to be efficacious, less likely to lead to adverse side effects, and, in many circumstances, more cost-effective for both the patient and society at large than current approaches to many different illnesses.
Learn the Top Ten considerations in-house counsel need to know when handling sensitive Protected Health Information ("PHI") and/or Personally Identifiable Information ("PII") in a healthcare setting in the United States, including the unique set of risks associated with this handling of data.
This primer examines the minimum benefits that must be included in order for a health insurance policy to comply with the US Affordable Care Act (ACA).
In this article, key questions are answered by leading practitioners regarding health care, pharmaceutical, and medical device industry laws and compliance in Italy.
This is a sample business development agreement, for a non-exclusive cooperative marketing relationship to promote collection services (governed by Ohio law).
This is a sample SRDP disclosure outline.
This is a sample request for proposal for valuation services.
This is a sample confidentiality and standstill agreement.
This is a sample agreement for telemedicine services.
This quick overview (QuickCounsel) describes how the U.S. Food and Drug Administration ("FDA") regulates the pre-marketing process for drugs and medical devices, and the steps that must be taken to obtain FDA authorization to market these products.